103 related articles for article (PubMed ID: 31047912)
1. National Trends in the Utilization of Androgen Deprivation Therapy for Very Low Risk Prostate Cancer.
May A; Henke J; Au D; Raza SJ; Davaro F; Hamilton Z; Siddiqui SA
Urology; 2019 Aug; 130():79-85. PubMed ID: 31047912
[TBL] [Abstract][Full Text] [Related]
2. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer.
Chen YW; Muralidhar V; Mahal BA; Nezolosky MD; Beard CJ; Choueiri TK; Hoffman KE; Martin NE; Orio PF; Sweeney CJ; Feng FY; Trinh QD; Nguyen PL
Brachytherapy; 2016; 15(6):695-700. PubMed ID: 27528590
[TBL] [Abstract][Full Text] [Related]
4. Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer.
Lin CC; Gray PJ; Jemal A; Efstathiou JA
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25957435
[TBL] [Abstract][Full Text] [Related]
5. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer.
Rusthoven CG; Jones BL; Flaig TW; Crawford ED; Koshy M; Sher DJ; Mahmood U; Chen RC; Chapin BF; Kavanagh BD; Pugh TJ
J Clin Oncol; 2016 Aug; 34(24):2835-42. PubMed ID: 27325855
[TBL] [Abstract][Full Text] [Related]
6. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
7. National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer.
Yang DD; Muralidhar V; Mahal BA; Labe SA; Nezolosky MD; Vastola ME; King MT; Martin NE; Orio PF; Choueiri TK; Trinh QD; Spratt DE; Hoffman KE; Feng FY; Nguyen PL
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):338-343. PubMed ID: 28463152
[TBL] [Abstract][Full Text] [Related]
8. Patterns of androgen deprivation therapies among men diagnosed with localised prostate cancer: a population-based study.
Lycken M; Garmo H; Adolfsson J; Stattin P; Holmberg L; Bill-Axelson A
Eur J Cancer; 2014 Jul; 50(10):1789-1798. PubMed ID: 24736041
[TBL] [Abstract][Full Text] [Related]
9. Trends and racial differences in the use of androgen deprivation therapy for metastatic prostate cancer.
Carson AP; Howard DL; Carpenter WR; Taylor YJ; Peacock S; Schenck AP; Godley PA
J Pain Symptom Manage; 2010 May; 39(5):872-81. PubMed ID: 20471547
[TBL] [Abstract][Full Text] [Related]
10. Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center.
Muralidhar V; Regan MM; Werner L; Nakabayashi M; Evan CP; Bellmunt J; Choueiri TK; Elfiky AA; Harshman LC; McKay RR; Pomerantz MM; Sweeney CJ; Taplin ME; Kantoff PW; Nguyen PL
Clin Genitourin Cancer; 2016 Aug; 14(4):e299-305. PubMed ID: 26778006
[TBL] [Abstract][Full Text] [Related]
11. Trends in the Use of Stereotactic Body Radiotherapy for Treatment of Prostate Cancer in the United States.
Mahase SS; D'Angelo D; Kang J; Hu JC; Barbieri CE; Nagar H
JAMA Netw Open; 2020 Feb; 3(2):e1920471. PubMed ID: 32022878
[TBL] [Abstract][Full Text] [Related]
12. Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States.
Gilbert SM; Kuo YF; Shahinian VB
Urol Oncol; 2011; 29(6):647-53. PubMed ID: 19926311
[TBL] [Abstract][Full Text] [Related]
13. Survival outcomes of radiotherapy with or without androgen-deprivation therapy for patients with intermediate-risk prostate cancer using the National Cancer Data Base.
Amini A; Rusthoven CG; Jones BL; Armstrong H; Raben D; Kavanagh BD
Urol Oncol; 2016 Apr; 34(4):165.e1-9. PubMed ID: 26699831
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
Falchook AD; Basak R; Mohiuddin JJ; Chen RC
Cancer; 2016 Aug; 122(15):2341-9. PubMed ID: 27191936
[TBL] [Abstract][Full Text] [Related]
15. Association between ischaemic bowel syndromes and androgen deprivation therapy in patients with prostate cancer: a retrospective cohort study.
Chiang IN; Huang CY; Pu YS; Chang CH; Muo CH; Chung CJ; Wang RY; Young TH
BMJ Open; 2017 Feb; 7(2):e012950. PubMed ID: 28246133
[TBL] [Abstract][Full Text] [Related]
16. Large institutional variations in use of androgen deprivation therapy with definitive radiotherapy in a population-based cohort of men with intermediate- and high-risk prostate cancer.
Ong WL; Foroudi F; Evans S; Millar J
BJU Int; 2017 Nov; 120 Suppl 3():35-42. PubMed ID: 28749017
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
[TBL] [Abstract][Full Text] [Related]
18. Variations in patterns of concurrent androgen deprivation therapy use based on dose escalation with external beam radiotherapy vs. brachytherapy boost for prostate cancer.
Mohiuddin JJ; Narayan V; Venigalla S; Vapiwala N
Brachytherapy; 2019; 18(3):322-331. PubMed ID: 30862436
[TBL] [Abstract][Full Text] [Related]
19. Reimbursement cuts and changes in urologist use of androgen deprivation therapy for prostate cancer.
Shahinian VB; Kuo YF
BMC Urol; 2015 Apr; 15():25. PubMed ID: 25885745
[TBL] [Abstract][Full Text] [Related]
20. Use of androgen deprivation therapy for metastatic prostate cancer in older men.
Keating NL; O'Malley AJ; McNaughton-Collins M; Oh WK; Smith MR
BJU Int; 2008 May; 101(9):1077-83. PubMed ID: 18190632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
